Therapeutic Programs Under Development
Sangamo’s robust and diverse pipeline of genomic medicines in clinical and preclinical stages of development encompass a breadth of distinct but complementary technical approaches. We are developing capabilities that allow us to design therapeutic approaches to resolve the underlying genetic causes of disease, using whichever technology is best suited to deliver that treatment. We prioritize research targets and clinical candidates where there is high unmet patient need, where the disease biology is understood, and where our suite of technologies has the potential to make a difference.
Our pipeline comprises a balance of wholly owned and partnered programs. We collaborate with partners when additional resources and therapeutic area expertise may help us bring our medicines to patients more quickly.
Gene-Edited Cell Therapy